# SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Study · id `cardio:ct-nct06054035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06054035](<https://clinicaltrials.gov/study/NCT06054035>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06054035

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

## Technical summary

Registry record NCT06054035. Randomized; double masking; primary purpose treatment. Start 2023-10-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT06054035, source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)
- Started: 2023-10-26 (actual) (ClinicalTrials.gov record NCT06054035, source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT06054035, source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT06054035, source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)
- Countries: Germany (ClinicalTrials.gov record NCT06054035, source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06054035-2026-09-15`, retrieved 2026-11-18)

## The registry's words

- Brief title: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
- Condition: Type2diabetes
- Condition: PreDiabetes
- Condition: Renal Failure
- Intervention (Drug): Dapagliflozin (Forxiga®)
- Intervention (Drug): Placebo matching Dapaglifolzin
- Intervention (Behavioral): Lifestyle Intervention
- Lead sponsor: University Hospital Tuebingen
- Lead sponsor class: OTHER
- Collaborator: German Federal Ministry of Education and Research
- Collaborator class: OTHER\_GOV
- Collaborator: German Center for Diabetes Research
- Collaborator class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as the lead sponsor: University Hospital Tuebingen (`cardio:org-university-hospital-tuebingen`)
- Registry lists this organization as a collaborator: German Federal Ministry of Education and Research (`cardio:org-german-federal-ministry-of-education-and-research`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 3c9e5c02ef460ee02fbade366960cd9bb6316a446d451ccfdc7bf793b76a9eaf
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
